Lurbinectedin (PM01183) with doxorubicin (DOX), an active treatment as second-line therapy in small cell lung cancer (SCLC).

被引：0
|
作者：
Forster, Martin
Calvo, Emiliano
Olmedo Garcia, Maria Eugenia
Pilar Lopez Criado, M.
Moreno, Victor
Soto-Matos, Arturo
Holgado, Esther
Brown, Nicholas F.
Flynn, Michael
Boni, Valentina
Guerra Alia, Eva
Szyldergemajn, Sergio A.
机构：
[1] UCL, London, England
[2] START Madrid, Ctr Integral Oncol Clara Campal, Madrid, Spain
[3] Ramon & Cajal Univ Hosp, Dept Med Oncol, Madrid, Spain
[4] MD Anderson Canc Ctr Madrid, Madrid, Spain
[5] Fdn Jimenez Diaz, E-28040 Madrid, Spain
[6] PharmaMar SAU, Madrid, Spain
[7] Hosp Madrid, Norte Sanchinarro, Spain
[8] Hosp Univ Ramon & Cajal, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7509
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer
    Desai, Aakash
    Smith, Caleb J.
    Ashara, Yash
    Orme, Jacob J.
    Zanwar, Saurabh
    Potter, Ashley
    Hocum, Craig
    Moffett, J. Nicole
    Schwecke, Anna J.
    Manochakian, Rami
    Lou, Yanyan
    Zhao, Yujie
    Ernani, Vinicius
    Savvides, Panos
    Molina, Julian
    Dimou, Anastasios
    Mansfield, Aaron S.
    Parikh, Kaushal
    Leventakos, Konstantinos
    CLINICAL LUNG CANCER, 2023, 24 (08) : 689 - +
  • [42] Second-line treatment of advanced non-small cell lung cancer
    Gridelli, Cesare
    Ardizzoni, Andrea
    Ciardiello, Fortunato
    Hanna, Nasser
    Heymach, John V.
    Perrone, Francesco
    Rosell, Rafael
    Shepherd, Frances A.
    Thatcher, Nick
    Vansteenkiste, Johan
    De Petris, Luigi
    Di Maio, Massimo
    De Marinis, Filippo
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (04) : 430 - 440
  • [43] CLINICAL ACTIVITY OF LURBINECTEDIN (PM01183) IN COMBINATION WITH GEMCITABINE (GEM) IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS): PRELIMINARY SUBGROUP ANALYSIS OF A PHASE IB STUDY
    Paz-Ares, Luis
    Calvo, E.
    Forster, M.
    Boni, V.
    Lopez Calderero, I.
    Benafif, S.
    Kahatt, C.
    Turnbull, S.
    Corral, J.
    Cubillo, A.
    Flynn, M.
    Luque Ibanez, M.
    Soto Matos-Pita, A.
    Szyldergemajn, S.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S569 - S569
  • [44] Real-World Effectiveness and Safety Profile of Lurbinectedin and Other Second-Line Treatments in Small Cell Lung Cancer
    Ganti, Apar Kishor
    Allan, Victoria
    Prince, Patricia
    Estrin, Adina
    Gautam, Nileesa
    Merola, Dave
    Boccuti, Anne
    Rengarajan, Badri
    Baratta, Cristina
    Li, Wenyan
    Cao, Yanyan
    Poole, Elizabeth M.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E50 - E51
  • [45] EP13.07-07 Exploring Outcomes in Second-line Therapy for Small Cell Lung Cancer with Brain Metastases: Lurbinectedin vs Others
    Se, B.
    Polani, F.
    Karovic, S.
    Dvergsten, E.
    Pierattini, C.
    Karim, N. Abdel
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S709 - S709
  • [46] Efficacy and safety of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer: Preliminary results of a phase 1 study.
    Cheng, Ying
    Wu, Chunjiao
    Chen, Lulu
    Xin, Ying
    Zhang, Liang
    Pan, Pinghua
    Wu, Lin
    Li, Juan
    Zhao, Yanqiu
    Li, Xingya
    Zhao, Jun
    Dong, Xiaorong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] ECONOMIC BURDEN IN ADULT PATIENTS WITH SMALL CELL LUNG CANCER (SCLC) RECEIVING SECOND-LINE THERAPY: A SYSTEMATIC LITERATURE REVIEW (SLR)
    Kwon, C.
    Nair, A. A.
    Harricharan, S.
    Zhang, X.
    VALUE IN HEALTH, 2022, 25 (07) : S393 - S393
  • [48] Prognostic factors for response and survival of second-line chemotherapy in patients with relapsed small cell lung cancer (SCLC)
    Kim, Y.
    Goto, K.
    Yoh, K.
    Niho, S.
    Ohmatsu, H.
    Kubota, K.
    Saijo, N.
    Nishiwaki, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [49] Lurbinectedin (PM01183), a selective inhibitor of active transcription, effectively eliminates both cancer cells and cancer stem cells in preclinical models of uterine cervical cancer
    Eriko Yokoi
    Seiji Mabuchi
    Kotaro Shimura
    Naoko Komura
    Katsumi Kozasa
    Hiromasa Kuroda
    Ryoko Takahashi
    Tomoyuki Sasano
    Mahiru Kawano
    Yuri Matsumoto
    Michiko Kodama
    Kae Hashimoto
    Kenjiro Sawada
    Tadashi Kimura
    Investigational New Drugs, 2019, 37 : 818 - 827
  • [50] ATLANTIS Trial: Phase III Study of PM01183/Doxorubicin vs. CAV or Topotecan in SCLC after One Platinum-Containing Line
    Farago, Anna
    Forster, Martin
    Paz-Ares, Luis
    Puparelli, Carmen
    Szyldergemajn, Sergio
    Lopez-Vilarino, Jose
    Moss, Keren
    Kahatt, Carmen
    Soto-Matos, Arturo
    Eugenia Olmedo, Maria
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1425 - S1425
12345